Neutropenia

Updated: April 24, 2023

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

amikacin and cefepime

febrile:

1.25 to 2.5 grams given intravenously twice a day divided in equal doses. The duration of treatment is 7-10 days

lipegfilgrastim

lipegfilgrastim is used in patients who are on chemotherapy to reduce neutropenic complications with a dose of one 6 mg Lonquex, a single pre-filled syringe for only a single administration per cycle of chemotherapy, which is given one day after cytotoxic chemotherapy

Dose Adjustments

No data available or established

lenograstim

It is a granulocyte colony-stimulating factor (GCSF) that functions as an immunostimulant and is used to treat neutropenia after bone marrow transplantation
Allowed intravenously (IV) for 30 minutes, diluted in isotonic saline solution, or subcutaneously (SC) at a dose of 150 mg (19.2 MIU) m2 per day, which should begin the day (not less than 24 hours) following transplantation. The maximum period is 28 days

Dose Adjustments

Limited data is available for renal or hepatic impairment

lenograstim

150 mcg/m2 (19.2 million IU/m2) daily via SC, beginning the day (not less than 24 hours) after the previous antineoplastic treatment. The maximum period is 28 days

Dose Adjustments

Limited data is available for renal or hepatic impairment

benegrastim (pending for FDA approval)

Pending for FDA approval

Dose Adjustments

N/A

lenograstim

In children above 2 years, 150 mcg/m2 (19.2 million IU/m2) daily via SC, beginning the day (not less than 24 hours) after the previous antineoplastic treatment and continuing until the predicted nadir has passed and the neutrophil count has stabilized. The maximum period is 28 days

Future Trends